Tempting as it may be to turn to full automation to meet burdensome requirements, the potential for hallucination and other issues means biopharma companies must proceed with caution.
{Categories} _Category: Takes{/Categories}
{URL}https://www.biospace.com/article/opinion-genai-is-not-a-one-size-fits-all-solution-for-regulatory-operations/{/URL}
{Author}unknown{/Author}
{Image}https://www.biospace.com/getasset/11fa5c8a-5abd-41bd-89e5-be302c835cd3/{/Image}
{Keywords}{/Keywords}
{Source}POV{/Source}
{Thumb}{/Thumb}